- The Medicines Co $MDCO presented at the Jefferies conference 6/7/11 (webcast link available on Upcoming Events page).
- MDCO recently licensed worldwide rights to captisol-enabled IV clopidogrel (aka Plavix) from Ligand $LGND (click here for LGND stock research page).
- Here are my notes (only those related to this LGND-related development...):
- IV clopidogrel- complements cangrelor product that is in a very large p3 trial
- MDCO looked at >400 business development (BD) opportunities in last 4 yrs
- MDCO hopes that this product could come to market late 2013 or 2014
- Will use 505b2 strategy for development and filing of this product (see this link so more info on this pathway). Now preparing drug material for dose ranging and PK/PD (pharmacokinetic/pharmacodynamic) study sometime in 2012 (LGND had said filing could occur around mid-2012, sound like this may be too aggressive a goal)
- anticipate 3 yr data exclusivity
RSS Feed
